General Information
Hanmi HM-TRIA-102
A Phase 1 Study to Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses Of HM15211 in Obese Subjects with NAFLD and in Subjects swith Nash
| Protocol | HM-TRIA-102 |
|---|---|
| Identifier | PO 22423 |
| UID | 8936d321-d492-4770-aa29-a766c6216659 |
| Status | Done - Archived |
| Phase | 1 |
| Category | NASH / Adult |
| Launch Year | 2019 |
| NCT Number | - |
| Created | 2018-12-06 11:25 |
| Last Updated | 2018-12-06 11:25 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-11-15 | No |
| Enrollment Open | 2019-01-03 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2018-12-19 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-10-28 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Hanmi Pharmaceuticals Co. Ltd |
|---|---|
| Division | Hanmi Pharmaceuticals Co. Ltd |
| Team | Hanmi Pharmaceuticals Co. Ltd |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ProSciento, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
